Jamjoom Pharmaceuticals Factory Company — Cyborg Score 7/10
Strong
Pharmaceuticals & Consumer Healthcare
Strategic Profile
The company focuses on developing, manufacturing, and distributing generic pharmaceuticals, cosmetics, and consumer healthcare products. Operating through pharmaceutical and consumer health segments with subsidiaries and 8 branches, the company leverages an extensive distribution network across multiple regions.
Cyborg Score Rationale
The company demonstrated strong growth in 2024 with revenue increasing 19.77% to 1.32 billion SAR and earnings rising 21.93% to 356.52 million SAR. Dividend yield of 2.01% in 2024 with a 60.08% payout ratio indicates shareholder-friendly capital allocation.
Top Insights
Strong growth momentum: 19.77% revenue growth and 21.93% earnings growth in 2024
Broad geographic presence: Products supplied in 36+ countries across GCC, Levant, North Africa, and other regions
Dual operating segments: Pharmaceutical products and consumer health products providing diversification
Strategic development: Recent non-binding term sheet signed (October 2025) for potential strategic partnership with pharmaceutical investment company
Named Competitors
Generic and branded pharmaceuticals — Major Saudi pharmaceutical manufacturer and competitor
Pharmaceutical products and cosmetics — Regional competitors in GCC pharmaceutical distribution
Recent Developments
(January 2026) Board of Directors recommendation to transfer statutory reserve balance to retained earnings
(October 2025) Signing of non-binding term sheet for potential strategic partnership with pharmaceutical investment company
(October 2025) Q3 2025 interim financial results announcement for nine-month period
Open the full interactive Jamjoom Pharmaceuticals Factory Company report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.